Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL567428 | 1.00 | LMNA (0.64) | LMNASMN1; SMN2RAB9ACA2POLB | |
| SCHEMBL5845241 | 1.00 | LMNA (0.64) | LMNASMN1; SMN2RAB9ACA2POLB | |
| SCHEMBL6973472 | 0.88 | CA2 (0.57) | LMNASMN1; SMN2RAB9ACA2ALDH1A1 | |
| SCHEMBL10832816 | 0.88 | CA2 (0.51) | LMNASMN1; SMN2RAB9ACA2ALDH1A1 | |
| SCHEMBL6973466 | 0.88 | CA2 (0.57) | LMNASMN1; SMN2RAB9ACA2ALDH1A1 | |
| SCHEMBL7966432 | 0.87 | LMNA (0.61) | LMNASMN1; SMN2RAB9ACA2POLB | |
| SCHEMBL11102654 | 0.87 | LMNA (0.48) | LMNASMN1; SMN2RAB9ACA2ALDH1A1 | |
| SCHEMBL6976444 | 0.86 | LMNA (0.48) | LMNASMN1; SMN2RAB9ACA2POLB | |
| SCHEMBL6976439 | 0.86 | LMNA (0.48) | LMNASMN1; SMN2RAB9ACA2POLB | |
| SCHEMBL7782073 | 0.86 | LMNA (0.48) | LMNASMN1; SMN2RAB9ACA2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065257-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | SMITH-SWINTOSKY VIRGINIA L (US) | 2012-03-15 | — | — | US | disclosed |
| EP-1968574-B1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF OBESITY | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-10 | — | — | EP | disclosed |
| EP-1968573-B1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MANIA AND BIPOLAR DISORDER | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-16 | — | — | EP | disclosed |
| EP-2276481-A1 | USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF ANXIETY | Janssen Pharmaceutica, N.V. (BE) | 2011-01-26 | — | — | EP | disclosed |
| US-5767116-A | TREATING PSYCHOSES | KNOLL ATKIENGESELLSCHAFT (DE) | 1998-06-16 | — | — | US | disclosed |
| EP-0717739-A1 | BICYCLIC AROMATIC COMPOUNDS AS THERAPEUTIC AGENTS | Knoll AG (DE) | 1996-06-26 | — | — | EP | disclosed |
| WO-1995007274-A1 | BICYCLIC AROMATIC COMPOUNDS AS THERAPEUTIC AGENTS | KNOLL AG (DE) | 1995-03-16 | — | — | WO | disclosed |
| EP-0199400-B1 | Substituted N-[(4-piperidinyl)alkyl] bicyclic condensed ozazol- and thiazolamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-09-26 | — | — | EP | disclosed |
| US-4826848-A | Antidepressive substituted N-[(4-piperidinyl)alkyl] bicyclic condensed oxazol- and thiazolamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1989-05-02 | — | — | US | disclosed |
| US-4749702-A | PARKINSON*S DISEASE, ENTEROKINESIA | JANSSEN PHARMACEUTICA N. V. (BE) | 1988-06-07 | — | — | US | disclosed |
| US-4689330-A | PARKINSON DISEASE | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-08-25 | — | — | US | disclosed |
| EP-0199400-A2 | Substituted N-[(4-piperidinyl)alkyl] bicyclic condensed ozazol- and thiazolamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065257-A1 | USE OF BENZO-FUSED HETEROCYLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF MIGRAINE | CNR2, FAAH2, CCKBR | LMNA 3339/4885SMN1; SMN2 1516/4885RAB9A 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.